GB2463833A - Methods and compositions for the treatment of neurological disorders - Google Patents
Methods and compositions for the treatment of neurological disorders Download PDFInfo
- Publication number
- GB2463833A GB2463833A GB1001047A GB201001047A GB2463833A GB 2463833 A GB2463833 A GB 2463833A GB 1001047 A GB1001047 A GB 1001047A GB 201001047 A GB201001047 A GB 201001047A GB 2463833 A GB2463833 A GB 2463833A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compositions
- methods
- neurological disorders
- treatment
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Methods and compositions are provided for preventing and treating neurological disorders, in particular Parkinson's disease.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94637407P | 2007-06-26 | 2007-06-26 | |
US95109607P | 2007-07-20 | 2007-07-20 | |
US3233408P | 2008-02-28 | 2008-02-28 | |
PCT/US2008/068442 WO2009003147A1 (en) | 2007-06-26 | 2008-06-26 | Methods and compositions for the treatment of neurological disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201001047D0 GB201001047D0 (en) | 2010-03-10 |
GB2463833A true GB2463833A (en) | 2010-03-31 |
GB2463833B GB2463833B (en) | 2012-02-08 |
Family
ID=40186043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1001047.8A Expired - Fee Related GB2463833B (en) | 2007-06-26 | 2008-06-26 | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110111014A1 (en) |
GB (1) | GB2463833B (en) |
WO (1) | WO2009003147A1 (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
SE0801267A0 (en) | 2008-05-29 | 2009-03-12 | Cunctus Ab | Method of a user unit, a user unit and a system comprising said user unit |
US9622669B2 (en) | 2008-06-13 | 2017-04-18 | Parkinson's Institute | Diagnosis of neurodegenerative disorders |
JP2012502915A (en) | 2008-09-15 | 2012-02-02 | バイオビスタ インコーポレイテッド | Compositions and methods for treating epilepsy |
WO2010087313A1 (en) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | Neurite elongation stimulator |
WO2010087306A1 (en) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | Anti-neurodegenerative disease agent |
JPWO2010087315A1 (en) * | 2009-01-29 | 2012-08-02 | 株式会社林原生物化学研究所 | Anti-Alzheimer's disease agent |
EP2579870B1 (en) * | 2010-06-09 | 2018-02-14 | Emory University | Trkb agonists and methods of use |
AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
WO2012018387A2 (en) | 2010-08-02 | 2012-02-09 | Population Diagnotics, Inc. | Compositions and methods for discovery of causative mutations in genetic disorders |
WO2012054936A1 (en) * | 2010-10-22 | 2012-04-26 | Barber Elizabeth K | Treatment of neurodegenerative disease |
EP2721145A4 (en) * | 2011-06-16 | 2014-12-10 | Parkinson S Inst | High through-put screening in skin fibroblasts with an alpha-synuclein triplication |
US10221454B2 (en) | 2011-10-10 | 2019-03-05 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
WO2013067451A2 (en) | 2011-11-04 | 2013-05-10 | Population Diagnostics Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
WO2013070981A2 (en) * | 2011-11-08 | 2013-05-16 | University Of Central Florida Research Foundation, Inc. | Treating er stress related disorders by stabilizing intracellular calcium homeostasis |
KR101339984B1 (en) | 2012-02-07 | 2013-12-10 | 부산대학교 산학협력단 | Pharmaceutical composition for preventing radiation-induced impairment of hippocampal neurogenesis comprising as Baicalein an active ingredient |
EP2812452B1 (en) | 2012-02-09 | 2020-05-27 | Population Bio, Inc. | Methods and compositions for screening and treating developmental disorders |
US20150018362A1 (en) | 2012-02-27 | 2015-01-15 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
EP2877461B1 (en) | 2012-07-27 | 2018-05-09 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
US9976180B2 (en) | 2012-09-14 | 2018-05-22 | Population Bio, Inc. | Methods for detecting a genetic variation in subjects with parkinsonism |
CA2922005A1 (en) | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
WO2014141280A1 (en) * | 2013-03-13 | 2014-09-18 | Abital Pharma Pipelines Ltd. | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |
EP2962687B1 (en) * | 2013-04-02 | 2019-06-05 | The Doshisha | Tau aggregation inhibitor |
WO2015136515A1 (en) * | 2014-03-13 | 2015-09-17 | Abital Pharma Pipelines Ltd. | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |
US9750753B1 (en) | 2014-06-17 | 2017-09-05 | University Of South Florida | Method of treating diseases associated with LRRK2 mutation using hexachlorophene |
WO2016025637A1 (en) | 2014-08-12 | 2016-02-18 | Loyola University Of Chicago | Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same |
US10724096B2 (en) | 2014-09-05 | 2020-07-28 | Population Bio, Inc. | Methods and compositions for inhibiting and treating neurological conditions |
US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
US20160106722A1 (en) | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
US10716517B1 (en) | 2014-11-26 | 2020-07-21 | Cerner Innovation, Inc. | Biomechanics abnormality identification |
CN105596321A (en) * | 2015-12-22 | 2016-05-25 | 贵州施普德生物科技有限公司 | Compound pharmaceutical composition for treating Parkinsonism and application of compound pharmaceutical composition |
US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10918628B2 (en) | 2016-10-11 | 2021-02-16 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Treatment of synucleinopathies |
JP2020502269A (en) * | 2016-12-13 | 2020-01-23 | コーブ バイオ エルエルシー | Methods and compositions for treating Parkinson's disease |
US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
CA3097521C (en) * | 2017-05-15 | 2023-10-17 | Axial Biotherapeutics, Inc. | Inhibitors of microbially induced amyloid |
US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
EP3727043A4 (en) * | 2017-12-22 | 2021-07-07 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
CN108079004A (en) * | 2018-01-15 | 2018-05-29 | 南通大学 | The application of amphotericin B and its derivative in quick anti-depression drug is prepared |
JP7432244B2 (en) * | 2018-04-13 | 2024-02-16 | ヒョン ユ、スン | Identification of granin as a pathogenic factor in Alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating Alzheimer's disease |
EP3572078A1 (en) * | 2018-05-24 | 2019-11-27 | ETH Zurich | Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases |
EP4177356A1 (en) | 2018-08-08 | 2023-05-10 | PML Screening, LLC | Methods for assessing risk of developing a viral disease using a genetic test |
CN111053744B (en) * | 2018-12-27 | 2021-12-10 | 北京安德普泰医疗科技有限公司 | Baicalin liposome and application thereof |
WO2020144753A1 (en) * | 2019-01-09 | 2020-07-16 | 公立大学法人大阪 | Prophylactic or therapeutic drug for neurodegenerative diseases |
KR102102868B1 (en) * | 2019-05-14 | 2020-04-23 | 주식회사 노브메타헬스 | A composition for preventing or treating neurodegenerative diseases comprising gossypetin |
US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
CN110559290A (en) * | 2019-08-29 | 2019-12-13 | 广东海洋大学 | Application of depside cyclic ether compound in preparing neuroprotective drug |
BR112022012766A2 (en) * | 2019-12-31 | 2022-09-06 | Abaxys Therapeutics | COMPOUND FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS |
AU2021206182A1 (en) * | 2020-01-06 | 2022-07-28 | AUM LifeTech, Inc. | Antisense oligonucleotides for treatment of neurological disorders |
US20210223268A1 (en) * | 2020-01-21 | 2021-07-22 | Board Of Regents Of The University Of Texas System | Discriminating parkinson's disease from multiple system atrophy using alpha-synuclein pmca |
US20220133700A1 (en) * | 2020-10-29 | 2022-05-05 | Thomas Winston | Compositions and methods for treating neurological disorders |
WO2023201042A1 (en) * | 2022-04-15 | 2023-10-19 | Menning Mark Michael | Emulsion formulations of poorly water-soluble compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316027B1 (en) * | 1995-08-18 | 2001-11-13 | R. P. Scherer Technologies, Inc. | Fast-dissolving dosage forms for dopamine agonists |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US20040152760A1 (en) * | 1999-12-30 | 2004-08-05 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
US20050143408A1 (en) * | 2000-08-17 | 2005-06-30 | Axon Biochemicals B.V. | Aporphine esters and their use in therapy |
US20060264466A1 (en) * | 2003-01-16 | 2006-11-23 | Weiner David M | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
JPS63214183A (en) * | 1987-03-03 | 1988-09-06 | Mitsui Norin Kk | Inhibitor of enzyme transforming angiotensin |
US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5358713A (en) * | 1990-02-23 | 1994-10-25 | Mitsui Norin Co., Ltd. | Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus |
PT689438E (en) * | 1993-03-26 | 2003-10-31 | Franciscus Wilhelmus He Merkus | PHARMACEUTICAL COMPOSITIONS FOR INTROMASSAL ADMINISTRATION OF APOMORPHINE |
US20030017998A1 (en) * | 1997-05-16 | 2003-01-23 | Snow Alan D. | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases |
ES2163234T3 (en) * | 1997-07-15 | 2002-01-16 | Unilever Nv | IMPROVEMENTS RELATED TO THEOPHOLVINE OR THE PRODUCTION OF THE SAME. |
US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
US20020151506A1 (en) * | 2000-12-29 | 2002-10-17 | Castillo Gerardo M. | Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders |
ES2387910T3 (en) * | 2001-03-15 | 2012-10-03 | Proteotech Inc. | Catechins for the treatment of fibrinogenesis in Alzheimer's disease, Parkinson's disease, systemic amyloidosis AA and other amyloid disorders |
US20030187011A1 (en) * | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
US20070116779A1 (en) * | 2005-11-23 | 2007-05-24 | Elizabeth Mazzio | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease |
-
2008
- 2008-06-26 US US12/666,626 patent/US20110111014A1/en not_active Abandoned
- 2008-06-26 GB GB1001047.8A patent/GB2463833B/en not_active Expired - Fee Related
- 2008-06-26 WO PCT/US2008/068442 patent/WO2009003147A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316027B1 (en) * | 1995-08-18 | 2001-11-13 | R. P. Scherer Technologies, Inc. | Fast-dissolving dosage forms for dopamine agonists |
US20040152760A1 (en) * | 1999-12-30 | 2004-08-05 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
US20050143408A1 (en) * | 2000-08-17 | 2005-06-30 | Axon Biochemicals B.V. | Aporphine esters and their use in therapy |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US20060264466A1 (en) * | 2003-01-16 | 2006-11-23 | Weiner David M | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Also Published As
Publication number | Publication date |
---|---|
GB201001047D0 (en) | 2010-03-10 |
WO2009003147A1 (en) | 2008-12-31 |
GB2463833B (en) | 2012-02-08 |
US20110111014A1 (en) | 2011-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
WO2007022506A3 (en) | Methods and compositions for treating neurological disease | |
TW200637522A (en) | Skin treatment articles and methods | |
MXPA06014510A (en) | Compositions and methods for treating inflammatory disorders. | |
EP1893216A4 (en) | Methods and compositions for the treatment of ocular disorders | |
WO2008021210A3 (en) | Methods and compositions for the treatment of neurodegenerative disorders | |
WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
MX2012004551A (en) | Novel compositions for preventing and/or treating lysosomal storage disorders. | |
WO2011065982A3 (en) | Polymorphisms associated with parkinson's disease | |
MX2010000465A (en) | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders. | |
WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
WO2008029276A8 (en) | Compositions and methods for the treatment of ophthalmic disease | |
SI2176252T1 (en) | 2, 3-dihydrobenzoš1, 4ćdioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases | |
WO2010014595A3 (en) | Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders | |
MX368459B (en) | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system. | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
WO2009009417A3 (en) | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion | |
MX2009009362A (en) | Novel dosage form. | |
TW200716153A (en) | Mitotic kinesin inhibitors and methods of use thereof | |
TW200728300A (en) | Therapeutic agents | |
MX2010005205A (en) | Active soluble post-translationally modified neuregulin isoforms. | |
HK1102626A1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
TW200716561A (en) | P38 inhibitors and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20150626 |